- HK$52.02bn
- HK$171.29bn
- CNY575.17bn
Sinopharm unit gets approval for clinical trials of mRNA COVID vaccine
Merck's COVID treatment expected to launch in China on Friday
Merck to take legal action against unauthorized distributors of its COVID treatment in China (updated)
Merck to take legal action against unauthorized distributors of its COVID treatment in China
HK-listed Sinopharm rises on regulatory approval for Merck's anti-COVID pill
China urges companies to ensure COVID-related medical supplies
Brief: China Traditional Chinese Medicine Noted Certain News Reports Dated 7 Dec
Sinopharm's second Chinese herb shot is potent
Brief: BlackRock Inc's Long Position In H-Shares Of Sinopharm Rises To 7.84% - HKEX Filing
Brief: Sinopharm Group Says 9-Mths Net Profit Attributable RMB5.86 Billion
Sinopharm rises most in 4 months on deal to sell Merck COVID drug in China
Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
Brief: BlackRock Inc's Long Position In H-Share Of Sinopharm Group Rises To 7.08% - HKEX Filing
Brief: Sinopharm Group Posts HY Profit Attributable RMB 3.69 Bln
HY Net Profit Attributable Rmb862.2 Million Versus Rmb765.9 Million
Brief: Sinopharm Reports Qtrly Profit Attributable RMB1.43 Billion
Brief: Sinopharm Group Reaches Strategic Cooperation With TSB Therapeutics (Beijing)
China's Brii jumps most in 4-1/2 months on COVID therapy tie-up with Sinopharm
Brief: Sinopharm Group Expects Original Annual Caps For Years Of 2022 And 2023 Will Not Be Sufficient